Ex vivo culture systems for hematopoietic cells

Paul C. Collins; E. Terry Papoutsakis; William M. Miller

doi:10.1016/S0958-1669(96)80017-6

Ex vivo culture systems for hematopoietic cells

Paul C. Collins, E. Terry Papoutsakis, William M. Miller^*

^*Corresponding author for this work

Chemical and Biological Engineering

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

During the past few years, hematopoietic cell culture technologies for transplantation therapies have progressed significantly on several fronts. Advances include the discoveries of the growth factors thrombopoietin and Flt-3 ligand, the development of a variety of bioreactor systems, and results from preliminary clinical trials that demonstrate the efficacy of ex vivo expanded hematopoietic cells for transplantation therapy.

Original language	English (US)
Pages (from-to)	223-230
Number of pages	8
Journal	Current Opinion in Biotechnology
Volume	7
Issue number	2
DOIs	https://doi.org/10.1016/S0958-1669(96)80017-6
State	Published - Apr 1996

ASJC Scopus subject areas

Biotechnology
Bioengineering
Biomedical Engineering

Access to Document

10.1016/S0958-1669(96)80017-6

Fingerprint Dive into the research topics of 'Ex vivo culture systems for hematopoietic cells'. Together they form a unique fingerprint.

Cite this

@article{ad28185305744003a6a25fca43dd6a49,

title = "Ex vivo culture systems for hematopoietic cells",

abstract = "During the past few years, hematopoietic cell culture technologies for transplantation therapies have progressed significantly on several fronts. Advances include the discoveries of the growth factors thrombopoietin and Flt-3 ligand, the development of a variety of bioreactor systems, and results from preliminary clinical trials that demonstrate the efficacy of ex vivo expanded hematopoietic cells for transplantation therapy.",

author = "Collins, {Paul C.} and Papoutsakis, {E. Terry} and Miller, {William M.}",

note = "Funding Information: Supported, in part, by NSF grant BES-9410751.",

year = "1996",

month = apr,

doi = "10.1016/S0958-1669(96)80017-6",

language = "English (US)",

volume = "7",

pages = "223--230",

journal = "Current Opinion in Biotechnology",

issn = "0958-1669",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Ex vivo culture systems for hematopoietic cells

AU - Collins, Paul C.

AU - Papoutsakis, E. Terry

AU - Miller, William M.

N1 - Funding Information: Supported, in part, by NSF grant BES-9410751.

PY - 1996/4

Y1 - 1996/4

N2 - During the past few years, hematopoietic cell culture technologies for transplantation therapies have progressed significantly on several fronts. Advances include the discoveries of the growth factors thrombopoietin and Flt-3 ligand, the development of a variety of bioreactor systems, and results from preliminary clinical trials that demonstrate the efficacy of ex vivo expanded hematopoietic cells for transplantation therapy.

AB - During the past few years, hematopoietic cell culture technologies for transplantation therapies have progressed significantly on several fronts. Advances include the discoveries of the growth factors thrombopoietin and Flt-3 ligand, the development of a variety of bioreactor systems, and results from preliminary clinical trials that demonstrate the efficacy of ex vivo expanded hematopoietic cells for transplantation therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029880414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029880414&partnerID=8YFLogxK

U2 - 10.1016/S0958-1669(96)80017-6

DO - 10.1016/S0958-1669(96)80017-6

M3 - Article

C2 - 8791333

AN - SCOPUS:0029880414

VL - 7

SP - 223

EP - 230

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

SN - 0958-1669

IS - 2

ER -